Page 152 - 2021_07-Haematologica-web

T. Yokokawa et al.
Philadelphia chromosome-negative classi-
cal myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018; 32(5):1057-1069.
30. Lindholt JS and Shi GP. Chronic inflamma- tion, immune response, and infection in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2006;31(5):453-463.
31. Grodin JL, Powell-Wiley TM, Ayers CR, et al. Circulating levels of matrix metallopro- teinase-9 and abdominal aortic pathology: from the Dallas Heart Study. Vasc Med. 2011;16(5):339-345.
32. Tefferi A, Nicolosi M, Penna D, et al. Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels. Blood Adv. 2018;2(15):1980-1984.
33. Fujita H, Hamaki T, Handa N, Ohwada A, Tomiyama J and Nishimura S. Hypocholesterolemia in patients with polycythemia vera. J Clin Exp Hematop. 2012;52(2):85-89.
34. Deng GG, Martin-McNulty B, Sukovich DA, et al. Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ Res. 2003;92(5):510-517.
35. Satoh K, Nigro P, Matoba T, et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med. 2009;15(6):649-656.
36. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N and Baxter BT. Matrix metallopro- teinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2002;110 (5):625-632.
37. Quintana RA and Taylor WR. Cellular mechanisms of aortic aneurysm formation. Circ Res. 2019;124(4):607-618.
38. Hernández Ríos M, Sorsa T, Obregón F, et al. Proteolytic roles of matrix metallopro- teinase (MMP)-13 during progression of chronic periodontitis: initial evidence for MMP-13/MMP-9 activation cascade. J Clin Periodontol. 2009;36(12):1011-1017.
39.Edelmann B, Gupta N, Schnoeder TM, et al. JAK2-V617F promotes venous thrombo- sis through β1/β2 integrin activation. J Clin Invest. 2018;128(10):4359-4371.
40. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloprolif- erative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
41. Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombo- cythemia: analysis of the prospective PT1 cohort. Blood. 2012;120(7):1409-1411.
42. Wehrle J, Seeger TS, Schwemmers S, Pfeifer D, Bulashevska A and Pahl HL. Transcription factor nuclear factor ery- throid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myelo- proliferative neoplasms. Haematologica. 2013;98(7):1073-1080.
43.Dutta A, Hutchison RE and Mohi G. Hmga2 promotes the development of myelofibrosis in Jak2(V617F) knockin mice by enhancing TGF-β1 and Cxcl12 path- ways. Blood. 2017;130(7):920-932.
44.Hadi T, Boytard L, Silvestro M, et al. Macrophage-derived netrin-1 promotes abdominal aortic aneurysm formation by activating MMP3 in vascular smooth mus- cle cells. Nat Commun. 2018;9:5022.
45. Eliason JL, Hannawa KK, Ailawadi G, et al. Neutrophil depletion inhibits experimental abdominal aortic aneurysm formation. Circulation. 2005;112(2):232-240.
46.Usui F, Shirasuna K, Kimura H, et al. Inflammasome activation by mitochondrial oxidative stress in macrophages leads to the development of angiotensin II-induced aortic aneurysm. Arterioscler Thromb Vasc Biol. 2015;35(1):127-136.
48.Li WQ, Dehnade F and Zafarullah M. Oncostatin M-induced matrix metallopro- teinase and tissue inhibitor of metallopro- teinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling path- way. J Immunol. 2001;166(1):3491-3498.
49. Ghosh A, Pechota A, Coleman D, Upchurch GR, Jr. and Eliason JL. Cigarette smoke-induced MMP2 and MMP9 secre- tion from aortic vascular smooth cells is mediated via the Jak/Stat pathway. Hum Pathol. 2015;46(2):284-294.
50. Kothari P, Pestana R, Mesraoua R, et al. IL- 6-mediated induction of matrix metallopro- teinase-9 is modulated by JAK-dependent IL-10 expression in macrophages. J Immunol. 2014;192(1):349-357.
51. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
52. Vannucchi AM and Harrison CN. Emerging treatments for classical myeloproliferative neoplasms. Blood. 2017;129(6):693-703.
53. Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT- II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701-1707.
54. Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016;101(7):821-829.
55. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of athero- sclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111-121.
56. Mas-Peiro S, Hoffmann J, Fichtlscherer S, et al. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergo- ing transcatheter aortic valve implantation. Eur Heart J. 2020;41(8):933-939.
57.Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associat- ed with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498.
47.
Wang Y, Ait-Oufella H, Herbin O, et al. TGF-beta activity protects against inflam- matory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010;120(2):422-432.
1922
haematologica | 2021; 106(7)